Balaji Sadhasivam

Dr. Balaji Sadhasivam

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2016 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
EPE. Sugantha Priya
E. Sugantha Priya
TKT. Sathish Kumar
T. Sathish Kumar
BSBalaji Sadhasivam
Balaji Sadhasivam
SBS. Bavithra
S. Bavithra
PSP. Raja Singh
P. Raja Singh
JAJ. Arunakaran
J. Arunakaran

EFEvan Floyd
Evan Floyd
SGSara Greenlee
Sara Greenlee
TOToluwanimi Oni
Toluwanimi Oni
BSBalaji Sadhasivam
Balaji Sadhasivam
Lurdes QueimadoLurdes Queimado
Lurdes Queimado
Many types of electronic cigarettes (ECs) are currently in use, but the default flow rate used to simulate puffing is centered on tobacco cigarette flow rates. CORESTA offers several methods and technical guides for evaluation of ECs but there are few puffing topography studies focusing on sub-ohm ECs; differences between real-world usage and that found in the literature appear large. This study focuses on how power and flow rate affect the nicotine yield of a sub-ohm EC. A puffing system (Puff3rd) has been designed and used to produce and collect EC aerosol. Nicotine yield was measured by GC–MS at three power levels and four flow rates. Data analysis was conducted in SAS using the MIXED procedure. Power, flow rate, and their interaction were all significant predictors of nicotine yield. Nicotine yield increased with both the vaping power and the puff flow rate with significant interaction of the two. Findings indicate that using the current CORESTA flow rate (1100 mL/min) to evaluate third-generation ECs underestimates nicotine yield and likely overestimates pyrolysis products. Real users are expected to have 2–3× the nicotine dose measured at 1100 mL/min, which could confound epidemiological studies seeking to link nicotine delivery to product satisfaction and acceptability.

Verified
Journal Article
Open access
PDF file
BSBalaji Sadhasivam
Balaji Sadhasivam
JMJimmy Manyanga
Jimmy Manyanga
VGVengatesh Ganapathy
Vengatesh Ganapathy
PAPawan Acharya
Pawan Acharya
CBCélia Bouharati
Célia Bouharati
Lurdes QueimadoLurdes Queimado
Lurdes Queimado
Chemotherapy and radiotherapy resistance are major obstacles in the long-term efficacy of head and neck squamous cell carcinoma (HNSCC) treatment. Secondhand smoke (SHS) exposure is common and has been proposed as an independent predictor of HNSCC recurrence and disease-free survival. However, the underlying mechanisms responsible for these negative patient outcomes are unknown. To assess the effects of SHS exposure on cisplatin efficacy in cancer cells, three distinct HNSCC cell lines were exposed to sidestream (SS) smoke, the main component of SHS, at concentrations mimicking the nicotine level seen in passive smokers’ saliva and treated with cisplatin (0.01–100 µM) for 48 h. Compared to cisplatin treatment alone, cancer cells exposed to both cisplatin and SS smoke extract showed significantly lower cisplatin-induced cell death and higher cell viability, IC50, and indefinite survival capacity. However, SS smoke extract exposure alone did not change cancer cell viability, cell death, or cell proliferation compared to unexposed control cancer cells. Mechanistically, exposure to SS smoke extract significantly reduced the expression of cisplatin influx transporter CTR1, and increased the expression of multidrug-resistant proteins ABCG2 and ATP7A. Our study is the first to document that exposure to SHS can increase cisplatin resistance by altering the expression of several proteins involved in multidrug resistance, thus increasing the cells’ capability to evade cisplatin-induced cell death. These findings emphasize the urgent need for clinicians to consider the potential role of SHS on treatment outcomes and to advise cancer patients and caregivers on the potential benefits of avoiding SHS exposure.

5 September 2026 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Open access
VGVengatesh Ganapathy
Vengatesh Ganapathy
GCGautham Chengizkhan
Gautham Chengizkhan
JMJimmy Manyanga
Jimmy Manyanga
MCMayilvanan Chinnaiyan
Mayilvanan Chinnaiyan
BSBalaji Sadhasivam
Balaji Sadhasivam
Lurdes QueimadoLurdes Queimado
Lurdes Queimado

23 June 2025
Verified
Book Chapter
Closed access
PDF file
RJRavindran Jaganathan
Ravindran Jaganathan
RRRajeswari Ravindran
Rajeswari Ravindran
NANur Aliaa Sorfina Binti Tajul Akmal
Nur Aliaa Sorfina Binti Tajul Akmal
Lurdes QueimadoLurdes Queimado
Lurdes Queimado
GCGautham Chengizkhan
Gautham Chengizkhan
IRIlangovan Ramachandran
Ilangovan Ramachandran
Colorectal cancer (CRC) is a leading cause of cancer-related mortality, driven by metastasis and drug resistance. Exosomes, nanosized extracellular vesicles, are promising candidates for CRC treatment. They facilitate intercellular communication, influencing tumour progression and the microenvironment. As natural carriers, exosomes transport proteins, lipids, and genetic material, making them ideal for drug delivery systems. They offer advantages over traditional methods, including penetration of biological barriers, minimal immunogenicity, and high biocompatibility. Exosomes deliver therapeutic agents like siRNAs, miRNAs, and chemotherapeutics directly to tumour cells, enhancing efficacy and minimizing off-target effects. Additionally, their potential as non-invasive biomarkers shows promise for early CRC detection. While current therapies often lead to adverse effects and resistance, exosomes selectively target cancer cells, sparing healthy tissue. Challenges with natural exosomes, such as scalability and stability, hinder clinical translation. Artificial exosomes address these limitations, enabling large-scale production and enhanced targeting capabilities. This chapter reviews exosomes as drug carriers in CRC, highlighting their potential to revolutionize treatment. It discusses advancements in artificial exosomes and strategies to overcome clinical challenges, emphasizing their promise in optimizing CRC therapy. <!----> <!----> <!----> <!---->

23 June 2025
Verified
Book Chapter
Closed access
PDF file
Ravi Manishkumar GorRavi Manishkumar Gor
Ravi Manishkumar Gor
Lurdes QueimadoLurdes Queimado
Lurdes Queimado
VGVengatesh Ganapathy
Vengatesh Ganapathy
EFEvan Floyd
Evan Floyd
SRSatish Ramalingam
Satish Ramalingam
BSBalaji Sadhasivam
Balaji Sadhasivam
Microrobots, also known as microbots, represent a booming field at the intersection of robotics and medicine, offering precise manipulation at the microscopic level. In the context of colorectal cancer (CRC) research, microrobots hold immense promise for both diagnostic and therapeutic applications. This chapter provides an overview of microrobots, highlighting their potential in revolutionizing CRC treatment through targeted drug delivery, enhanced diagnostic procedures, and immunomodulation. Key topics discussed include the design considerations for microrobots in CRC applications, implications for CRC diagnosis and treatment, innovative drug delivery strategies, and immunomodulation approaches. Challenges such as biocompatibility, safety concerns, regulatory hurdles, and ethical considerations are also addressed. By exploring advancements in microrobot technology and interdisciplinary collaborations, this chapter elucidates the potential of microrobots to transform CRC research and treatment, offering new avenues for improving patient outcomes. <!----> <!----> <!----> <!---->